American Eagle, Cardinal Health, Valeant Downgraded

American Eagle, Cardinal Health, and Valeant stocks received bearish analyst attention

Apr 18, 2017 at 10:09 AM
facebook X logo linkedin


Analysts are weighing in on retail stock American Eagle, drug distributor Cardinal Health Inc (NYSE:CAH), and pharma firm Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Here's a quick roundup of today's bearish brokerage notes on AEO stock, as well as CAH and VRX shares.

AEO Stock Sinks on Downgrade

B. Riley lowered its rating on AEO to "neutral" from "buy," and also slashed its price target to $15 from $18. American Eagle shares have dropped 1.3% to $13.25 on the bearish note, continuing their downtrend that started in late-November, after the stock peaked at $19. In fact, AEO is fresh off an April 5 record low of $13.04. There's plenty of room left for downgrades, too. Despite AEO stock's technical troubles, half of its 18 covering analysts still maintain a "buy" or better opinion, with just one "sell" assessment to be found.

Cardinal Health Gaps Lower on Guidance, Medtronic Deal

CAH has gapped 11.4% lower to trade at $72.48, pressured by a disappointing full-year earnings forecast, and news the company will buy $6.1 billion worth of assets from Medtronic Plc (NYSE:MDT). Making matters worse, Fitch downwardly revised its outlook to "negative," in response. Today's bear gap has Cardinal Health Inc on the short-sale restricted list, and not far from its year-to-date breakeven mark. Plus, bullish options traders could be in trouble. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), CAH stock's 10-day call/put volume ratio of 3.50 is just 9 percentage points from an annual high -- suggesting a near-extreme preference for calls over puts.

Deutsche Bank Drills Valeant Pharmaceuticals Stock

VRX is extending its long-term descent, down 3.7% at $9.13 and fresh off an eight-year low of $9.06. Crushing the stock is a price-target cut to $18 from $19 at Deutsche Bank, which is just more of the same. Specifically, among the 11 analysts tracking Valeant Pharmaceuticals Intl Inc, nine have dished out a "hold" or "strong sell" rating. The brokerage crowd isn't alone in its skepticism, either. For example, 15% of VRX stock's float is dedicated to short interest, following a 33.5% jump in the past two reporting periods.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI